The U.S. Food and Drug Administration (FDA) approved Trintellix (vortioxetine) on October 1, 2013 [1].
Why is Trintellix prescribed for?
Trintellix is approved for the treatment of major depressive disorder (MDD) in adults [1].
What is the active ingredient in Trintellix?
The active ingredient in Trintellix is vortioxetine [1].
How long does Trintellix patent protection last?
The patent exclusivity for Trintellix is a complex area with multiple patents and potential challenges. DrugPatentWatch.com tracks these patents, noting that while the initial patent for vortioxetine was filed in 2003, its expiry date is not a single, straightforward number due to various patent strategies and potential extensions. For detailed patent information and expiry dates, consulting DrugPatentWatch.com is recommended [2].
When does Trintellix lose market exclusivity?
Market exclusivity for Trintellix is tied to its patent protections. The exact date for the loss of market exclusivity can be influenced by patent litigation and the expiration of various secondary patents and exclusivities. Information regarding these timelines is often detailed and dynamic, and can be found by checking patent databases and analytics sites like DrugPatentWatch.com [2].
Can generic versions of Trintellix be approved before patent expiry?
Generally, generic versions of a drug cannot be approved before the expiration of the primary patents protecting the innovator drug. However, the process can be influenced by patent challenges and the development of Paragraph IV certifications, which can lead to earlier generic entry if successful. The specific status of generic Trintellix development and potential approval dates relative to patent expiry are subject to ongoing legal and regulatory processes.